Condition: Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia · Clonal Cytopenia of Undetermined Significance · Sponsor: M.D. Anderson Cancer Center
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
This description comes directly from the study's public registry record.
Kelly Chien, MD · (713) 745-7584 · kchien@mdanderson.org
Always discuss trial participation with your own doctor first.
| University of Miami | Miami, Florida, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06566742